Bone mineral density is reduced by telmisartan in male spontaneously hypertensive rats.
CONCLUSION: Results showed that telmisartan negatively affected bones suggesting that caution should be taken in possible therapeutic applications for protecting bone health in hypertensive conditions. More studies are necessary to clarify the mechanisms through which telmisartan favors bone loss in this model. PMID: 27607362 [PubMed - as supplied by publisher]
ConclusionCollectively, these results confirm the potential of E. mulungu for asthma treatment, through modulation of inflammatory response, supporting its ethnopharmacological use for respiratory diseases.graphical abstract
CONCLUSION: Three-monthly bolus vitamin D dosing regimens administered either as 1000 or 400 IU/day prevent bone loss in children with DTNS who require long-term steroids. Overall, three-monthly bolus supplemental prophylactic vitamin D, either 1000 or 400 IU/day, would seem to be an effective strategy for preventing bone loss in children with DTNS, as evidenced by the extremely low rates of bone loss (3.3% in each group), and is useful for delivering optimal care to children with DTNS. However, since this study was designed as an equivalence trial and not a superiority trial, further studies are required to demonstrate th...
ConclusionsWhile change in BMI is likely to be a rough proxy for change in PFat measured by DXA in longitudinal studies of adolescent females, this is not the case for adolescent males, where increased BMI is likely to correspond with decreased PFat. Consequently, inferences from longitudinal studies of adolescents which have assumed that an increase in BMI (or BMI Z-scores or percentiles) represents an increase in adiposity require reconsideration.
The first analyses of body composition were used for analyzing muscle loss in astronauts or for evaluating dietary regimes in obese patients , but during recent decades body analyses have gained increasing interest when evaluating cancer cachexia  and critically ill patients . Initial methodology was based on dual-energy X-ray absorptiometry (DXA), under-water weighing and bioimpedance . These techniques, however, could not distinguish between muscle groups or between subcutaneous and intra-abdominal fat.
Interpretation of pediatric bone mineral density by dual energy absorptiometry (DXA) requires adjustment for height (Ht). This is often not easily obtainable in nonambulant subjects.
The aims of this study are (1) to compare dual-energy X-ray absorptiometry (DEXA) and bioimpedance for body composition measurements in nondialysis patients with chronic kidney disease, and (2) to investigate factors associated with any measurement differences.
Despite evidence suggesting caution, employment of body mass index (BMI, kg.m −2) as a proxy for percentage of body fat (PFat) in longitudinal studies of children and adolescents remains commonplace. Our objective was to test the validity of change in BMI as a proxy for change in PFat measured by dual-energy X-ray absorptiometry (DXA) during adolescence.
Publication date: September 2018Source: Diabetes &Metabolic Syndrome: Clinical Research &Reviews, Volume 12, Issue 5Author(s): Letícia Dinis da C. Braga, Amelio F. Godoy-Matos, Priscila de Oliveira Siciliano, José Otávio do Amaral Corrêa, Denise Pires CarvalhoAbstractAimsDipeptidyl peptidase-4 (DPP4) is an adipokine with greater expression in visceral fat and related with insulin resistance (IR). Polycystic ovary syndrome (PCOS) is also associated with IR. Our study aims to evaluate DPP4 activity in PCOS.Materials and MethodsThirty PCOS patients were compared to 28 healthy women. Body com...
CONCLUSION: Early detection of critical illness neuromyo-pathy could be beneficial for improving the standards of intensive care, and thus reducing the risk of mortality in these patients. PMID: 30080234 [PubMed - as supplied by publisher]
Condition: Eosinophilic Esophagitis Interventions: Diagnostic Test: Bone Mineral Density (DEXA) scan; Diagnostic Test: Vitamin D Measurement; Diagnostic Test: Height measurement; Other: Assessment of medication compliance Sponsors: Arkansas Children's Hospital Research Institute; University of Arkansas Not yet recruiting